Discordance of Pathological Thin Melanoma Thickness and T Stage in SEER Registry: Impacts on Clinical Management and Research Directions.

Zhichao Wang,Haizhou Li,Xinyang Liu,Jinhong Bae,Xin Huang,Yashan Gao,Xiangwen Xu,Jihan Guo,Lin Lu,Tao Zan,Qingfeng Li

DOI: https://doi.org/10.18632/oncotarget.21980

2017-01-01

Oncotarget

Abstract:BACKGROUND:Ultrathin melanoma was previously demonstrated to have higher risk for melanoma-specific mortality using SEER database. However, these guideline-changing conclusions has been recently challenged by miscoding of thickness. This present study was performed to assess the prognosis of thin and ultrathin melanoma using only surgically-treated, pathologically confirmed and after removal of discordant cases.METHODS:Melanoma patients from SEER database who were initially diagnosed with histologically confirmed and surgically treated melanoma from 1998 to 2012 were included. Subjects with discordance between T stage and tumor thickness were excluded. Kaplan-Meier curves, log-rank test and multivariate Cox proportional hazards regression models were used.RESULTS:55,754 patients met the strict inclusion criteria, but 16 (0.02%) and 803 (1.4%) patients were removed due to T0 stage and discordance between T stage and thickness, respectively. Therefore, 54,935 patients entered the analyses, among which 52,751 were LN negative and 2,184 were LN positive. In either overall or LN-negative patients, a straightforward dose-effect relationship of larger thickness with increasing mortality was observed. In contrast, in LN positive patients, the T1 subgroup demonstrated a similar survival with tumors in T2 mm subgroup. Multivariable analysis revealed same pattern, and significant interaction between T stage and LN involvement was found. Further categorizing T1 melanoma into 10 equal 0.10 mm increments demonstrated an unexpected "N"-shaped pattern of mortality in overall and LN negative ultrathin melanoma but not in LN positive melanoma.CONCLUSIONS:No difference in mortality was observed in T1-3 tumors with LN involvement. External and independent validation studies are warranted.